初级和二级医疗中光化性角化病的医疗资源利用与管理:一项互补性数据库分析
本研究通过三个互补数据源回顾性分析荷兰光化性角化病(AK)患者的医疗利用与管理。在人群队列中,69%筛查确诊AK者既往无AK相关全科就诊记录;全科医生最常用冷冻治疗(78%),局部药物使用极少(2%),31%首诊即转诊且转诊率未按风险分层;二级医疗随访率56%但5年内后续皮肤恶性肿瘤索赔仅18%。结论认为AK管理在初级和二级医疗均与指南存在偏差。
要点
- 筛查确诊AK者中69%既往无AK相关全科就诊记录,广泛AK者该比例为50%。
- 全科医生冷冻治疗使用率78%,局部药物仅2%;皮肤科医生冷冻治疗41-56%,局部药物13-21%。
- 首次AK相关全科就诊中31%转诊皮肤科,转诊可能性在低危与高危患者间相当,与2017年荷兰全科医生指南不一致。
核心结论
- AK管理在初级和二级医疗似乎均与指南存在偏差,导致医疗资源利用效率低下和二级医疗负担过重。
- 作者认为,致力于更好的风险区分和指南依从性可能有助于提高AK管理效率。
研究设计与样本
- 回顾性队列研究,使用三个互补数据源描述荷兰AK患者的诊疗、随访和管理。
- 数据源包括基于人群的队列研究(鹿特丹研究)、常规全科医生记录(综合初级医疗信息)和全国索赔数据(DRG信息系统)。
主要发现
- 在基于人群的队列(鹿特丹研究)中,皮肤筛查访视期间确诊AK的参与者有69%(918/1322)既往全科记录中无AK相关就诊。
- 广泛AK(即≥10个AK)参与者(n=270)中该比例为50%。
- 全科医生最常用的AK治疗是冷冻治疗(78%),皮肤科医生为41-56%;局部药物是皮肤科医生第二常用治疗(13-21%),但在初级医疗中很少使用(2%)。
- 首次AK相关全科就诊中31%(171/554)转诊至皮肤科医生,转诊可能性在低危和高危患者间相当。
- 每年有40000例新索赔被标记为皮肤癌前病变,占所有皮肤科索赔的13%;二级医疗中广泛随访率登记为56%,而5年内仅18%获得后续皮肤恶性肿瘤索赔。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The high prevalence of actinic keratosis (AK) requires the optimal use of healthcare resources. OBJECTIVES: To gain insight in to the healthcare utilization of people with AK in a population-based cohort, and the management of AK in a primary and secondary care setting. METHODS: A retrospective cohort study using three complementary data sources was conducted to describe the use of care, diagnosis, treatment and follow-up of patients with AK in the Netherlands. Data sources consisted of a population-based cohort study (Rotterdam Study), routine general practitioner (GP) records (Integrated Primary Care Information) and nationwide claims data (DRG Information System). RESULTS: In the population-based cohort (Rotterdam Study), 69% (918 of 1322) of participants diagnosed with AK during a skin-screening visit had no previous AK-related visit in their GP record. This proportion was 50% for participants with extensive AK (i.e. ≥ 10 AKs; n = 270). Cryotherapy was the most used AK treatment by both GPs (78%) and dermatologists (41-56%). Topical agents were the second most used treatment by dermatologists (13-21%) but were rarely applied in primary care (2%). During the first AK-related GP visit, 31% (171 of 554) were referred to a dermatologist, and the likelihood of being referred was comparable between low- and high-risk patients, which is inconsistent with the Dutch general practitioner guidelines for 'suspicious skin lesions' from 2017. Annually, 40 000 new claims representing 13% of all dermatology claims were labelled as cutaneous premalignancy. Extensive follow-up rates (56%) in secondary care were registered, while only 18% received a claim for a subsequent cutaneous malignancy in 5 years. CONCLUSIONS: AK management seems to diverge from guidelines in both primary and secondary care. Underutilization of field treatments, inappropriate treatments and high referral rates without proper risk stratification in primary care, combined with extensive follow-up in secondary care result in the inefficient use of healthcare resources and overburdening in secondary care. Efforts directed to better risk differentiation and guideline adherence may prove useful in increasing the efficiency in AK management. What's already known about this topic? The prevalence of actinic keratosis (AK) is high and, in particular, multiple AKs are a strong skin cancer predictor. The high prevalence of AK requires optimal use of healthcare resources. Nevertheless, (population based) AK healthcare utilization and management data are very rare. What does this study add? Although AK-related care already consumes substantial resources, about 70% of the AK population has never received care. Primary care AK management demonstrated underutilization of topical therapies and high referral rates without proper risk stratification, while in secondary care the extensive follow-up schedules were applied. This inefficient use of healthcare resources highlights the need for better harmonization and risk stratification to increase the efficiency of AK care.
引用
- Noels EC, Hollestein LM, van Egmond S, et al. Healthcare utilization and management of actinic keratosis in primary and secondary care: a complementary database analysis. Br J Dermatol. 2019. PMID: 30636037. doi:10.1111/bjd.17632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。